Simon F Lacey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8561162/publications.pdf

Version: 2024-02-01

67	22,141	66234	95083
papers	citations	42 h-index	68 g-index

71	71	71	21750
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood, 2022, 139, 1026-1038.	0.6	67
2	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 2022, 602, 503-509.	13.7	369
3	PSMA-targeting TGFÎ²-insensitive armored CAR Tâ€‰cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine, 2022, 28, 724-734.	15.2	171
4	PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response. Frontiers in Immunology, 2022, 13, .	2.2	10
5	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	3.2	17
6	Autologous CD4ÂT Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy, 2021, 29, 626-635.	3.7	3
7	Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. British Journal of Haematology, 2021, 193, 851-855.	1.2	6
8	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine, 2021, 27, 842-850.	15.2	88
9	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation, 2021, 131, .	3.9	52
10	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Frontiers in Oncology, 2021, 11, 669071.	1.3	34
11	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	45
12	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6580-6590.	3.2	15
13	An NK-like CAR TÂcell transition in CAR TÂcell dysfunction. Cell, 2021, 184, 6081-6100.e26.	13.5	160
14	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 415-422.	0.8	162
15	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. Blood Advances, 2020, 4, 4292-4295.	2.5	9
16	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 2020, 369, .	6.0	1,280
17	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy, 2020, 28, 2367-2378.	3.7	32
18	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances, 2020, 4, 5174-5183.	2.5	30

#	Article	IF	Citations
19	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. Blood, 2020, 136, 1980-1983.	0.6	19
20	First Trial of CRISPR-Edited T cells in Lung Cancer. Trends in Molecular Medicine, 2020, 26, 713-715.	3.5	20
21	CRISPR-engineered T cells in patients with refractory cancer. Science, 2020, 367, .	6.0	872
22	Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis*. Critical Care Medicine, 2020, 48, 344-352.	0.4	20
23	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 2862-2871.	0.8	102
24	Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. OncoImmunology, 2020, 9, 1676615.	2.1	33
25	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Molecular Therapy, 2019, 27, 1919-1929.	3.7	220
26	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Advances, 2019, 3, 2487-2490.	2.5	35
27	Engineered T Cell Therapies from a Drug Development Viewpoint. Engineering, 2019, 5, 140-149.	3.2	8
28	B cell maturation antigenâ€“specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221.	3.9	513
29	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019, 130, 673-685.	3.9	78
30	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood, 2019, 134, 49-49.	0.6	10
31	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, 2019, 134, 1863-1863.	0.6	13
32	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 563-571.	15.2	1,150
33	Biomarkers in chimeric antigen receptor T-cell therapy. Biomarkers in Medicine, 2018, 12, 415-418.	0.6	14
34	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology, 2018, 155, 29-32.	0.6	337
35	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy, 2018, 26, 269-279.	3.7	90
36	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, .	2.3	140

#	Article	IF	Citations
37	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, 2018, 9, 2740.	2.2	58
38	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1468956.	2.1	88
39	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 2018, 24, 1499-1503.	15.2	459
40	Neurotoxicity after CTL019 in a pediatric and young adult cohort. Annals of Neurology, 2018, 84, 537-546.	2.8	82
41	Dominant-Negative TGF-Î² Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Molecular Therapy, 2018, 26, 1855-1866.	3.7	406
42	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558, 307-312.	13.7	574
43	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight, 2018, 3, .	2.3	412
44	Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunology Research, 2018, 6, 1100-1109.	1.6	189
45	PD-1 blockade modulates chimeric antigen receptor (CAR)â€“modified T cells: refueling the CAR. Blood, 2017, 129, 1039-1041.	0.6	393
46	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017, 130, 2317-2325.	0.6	273
47	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine, 2017, 9, .	5.8	1,116
48	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England Journal of Medicine, 2017, 377, 2545-2554.	13.9	1,390
49	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunology Research, 2017, 5, 1152-1161.	1.6	309
50	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathogens, 2017, 13, e1006613.	2.1	106
51	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of Immunological Methods, 2016, 434, 1-8.	0.6	150
52	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, 2016, 6, 664-679.	7.7	811
53	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 127, 1117-1127.	0.6	381
54	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood, 2016, 128, 360-370.	0.6	190

#	Article	IF	Citations
55	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research, 2016, 22, 2684-2696.	3.2	157
56	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 57-57.	0.6	18
57	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood, 2016, 128, 5702-5702.	0.6	31
58	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974.	0.6	28
59	Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2067-2067.	0.8	17
60	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. Journal of Clinical Oncology, 2016, 34, 3011-3011.	0.8	98
61	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v110.4-v111.	0.6	10
62	NY-ESO-1â€“specific TCRâ€“engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 2015, 21, 914-921.	15.2	728
63	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	5.8	1,402
64	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	7.7	997
65	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. New England Journal of Medicine, 2015, 373, 1040-1047.	13.9	511
66	Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine, 2014, 371, 1507-1517.	13.9	4,444
67	Biomarkers in T-cell therapy clinical trials. Cytotherapy, 2013, 15, 632-640.	0.3	7